Key Events This Week
3 Aug: Heavy put option activity amid bearish hedging
4 Aug: Valuation shift from very expensive to expensive
7 Aug: Week closes at ₹1,949.00 (-2.03%)
3 August: Heavy Put Option Activity Signals Bearish Hedging
On 3 August 2026, Sun Pharma’s stock price declined by 1.98% to close at ₹1,950.00, despite the Sensex gaining 0.82% that day. This drop coincided with a surge in put option activity, particularly at the ₹1,940 strike expiring on 25 August, where 2,707 contracts were traded generating a turnover of ₹291.25 lakhs. The open interest of 845 contracts at this strike indicated sustained bearish positioning or hedging by investors.
The stock had recently touched an intraday 52-week high of ₹2,046.90, but the heavy put option volume suggested caution among traders anticipating potential near-term volatility or a correction. The strike price chosen for puts was strategically close to the market price, reflecting a protective stance amid a broadly bullish technical trend supported by the stock’s position above key moving averages.
This activity highlighted a nuanced market sentiment where investors balanced optimism on fundamentals with tactical risk management, especially as the August expiry approached. The pharmaceutical sector’s mixed performance and broader market uncertainties likely contributed to this cautious positioning.
Built for the long haul! Consecutive quarters of strong growth landed this Small Cap from Chemicals on our Reliable Performers list. Sustainable gains are clearly ahead!
- - Long-term growth stock
- - Multi-quarter performance
- - Sustainable gains ahead
4 August: Valuation Shift Indicates Renewed Price Attractiveness
On 4 August, Sun Pharma’s share price marginally recovered, closing at ₹1,960.00, up 0.51% from the previous day, while the Sensex declined 0.14%. This day also saw a significant valuation reassessment, with the stock’s rating shifting from 'very expensive' to 'expensive'.
The price-to-earnings (P/E) ratio stood at 37.03, down from previous levels that had classified the stock as very expensive. The price-to-book value (P/BV) ratio was 5.60, indicating a premium valuation but with a slight moderation. Other multiples such as EV to EBIT (29.58) and EV to EBITDA (24.65) remained elevated, consistent with Sun Pharma’s large-cap status.
Comparatively, peers like Divi’s Laboratories and Torrent Pharmaceuticals maintained very expensive valuations with P/E ratios of 74.14 and 85.41 respectively, while Cipla was also expensive but at a lower P/E of 33.16. This relative valuation shift suggests Sun Pharma may offer a more balanced risk-reward profile within the sector.
Financial metrics remained robust, with a return on capital employed (ROCE) of 26.58% and return on equity (ROE) of 14.92%, underscoring operational efficiency. The stock’s year-to-date return of 13.39% outpaced the Sensex’s decline of 7.72%, reinforcing its resilience despite recent price consolidation.
5-7 August: Consolidation Amid Mixed Market Movements
From 5 to 7 August, Sun Pharma’s stock price fluctuated modestly, closing at ₹1,949.00 on 7 August, a slight 0.26% gain on the final day but a net decline of 2.03% for the week. The Sensex, in contrast, rose 1.13% over the same period, highlighting the stock’s underperformance.
Trading volumes varied, with a notable spike on 5 August at 568,888 shares, coinciding with a 0.56% price decline. The stock remained above key support levels but below its recent highs, reflecting investor caution amid the ongoing valuation recalibration and broader market volatility.
The mixed price action and moderate volume suggest a phase of consolidation as investors digest the implications of the valuation shift and the heavy put option activity observed earlier in the week.
Want to dive deeper on Sun Pharmaceutical Industries Ltd? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-08-03 | ₹1,950.00 | -1.98% | 36,985.17 | +0.82% |
| 2026-08-04 | ₹1,960.00 | +0.51% | 36,933.47 | -0.14% |
| 2026-08-05 | ₹1,949.00 | -0.56% | 37,074.66 | +0.38% |
| 2026-08-06 | ₹1,944.00 | -0.26% | 37,177.57 | +0.28% |
| 2026-08-07 | ₹1,949.00 | +0.26% | 37,099.57 | -0.21% |
Key Takeaways
Positive Signals: Sun Pharma’s fundamentals remain strong with robust ROCE of 26.58% and ROE of 14.92%, supporting its premium valuation. The recent valuation shift from very expensive to expensive improves price attractiveness relative to peers, and the stock continues to outperform the Sensex on a year-to-date and longer-term basis.
Cautionary Signals: The heavy put option activity at the ₹1,940 strike ahead of the August expiry indicates investor hedging and expectations of potential near-term volatility or correction. The stock’s 2.03% weekly decline contrasted with the Sensex’s 1.13% gain, signalling short-term underperformance and consolidation after recent highs.
Investors should balance the company’s strong operational metrics and relative valuation appeal with the tactical bearish positioning evident in the options market and the mixed price action observed during the week.
Conclusion
Sun Pharmaceutical Industries Ltd’s week was characterised by a complex interplay of bullish fundamentals and cautious market sentiment. While the stock’s valuation recalibration and strong financial returns underpin its quality status, the surge in put option activity and weekly price decline highlight investor prudence amid broader market uncertainties. The stock’s underperformance relative to the Sensex suggests a period of consolidation, with risk management strategies playing a key role for market participants. Monitoring option open interest and price trends in the coming weeks will be essential to gauge evolving sentiment and potential directional shifts.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
